ASG-22CE
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ASG-22CE, covering 2024-11-01 to 2024-11-01. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 [Phase 1]